

# Irma Airoidi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4479872/publications.pdf>

Version: 2024-02-01

58  
papers

2,631  
citations

147801  
31  
h-index

182427  
51  
g-index

59  
all docs

59  
docs citations

59  
times ranked

4121  
citing authors

#	ARTICLE	IF	CITATIONS
1	Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	13
2	EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 483-496.	4.4	15
3	Zoledronic acid boosts $\gamma$ T-cell activity in children receiving $\alpha$ T and CD19 <sup>+</sup> cell-depleted grafts from an HLA-haplo-identical donor. <i>Onc Immunology</i> , 2017, 6, e1216291.	4.6	76
4	Interleukin-30 Promotes Breast Cancer Growth and Progression. <i>Cancer Research</i> , 2016, 76, 6218-6229.	0.9	32
5	The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1 $\alpha$ inhibition in myeloma cells. <i>Haematologica</i> , 2016, 101, e107-e110.	3.5	11
6	IL12RB2 Polymorphisms correlate with risk of lung adenocarcinoma. <i>Immunobiology</i> , 2016, 221, 291-299.	1.9	6
7	SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis. <i>Oncotarget</i> , 2016, 7, 12372-12385.	1.8	49
8	$\gamma$ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR $\alpha\beta$ /CD19 <sup>+</sup> lymphocytes. <i>Blood</i> , 2015, 125, 2349-2358.	1.4	224
9	IL-27 induces the expression of IDO and PD-L1 in human cancer cells. <i>Oncotarget</i> , 2015, 6, 43267-43280.	1.8	115
10	<i>SNAI2/Slug</i> gene is silenced in prostate cancer and regulates neuroendocrine differentiation, metastasis-suppressor and pluripotency gene expression. <i>Oncotarget</i> , 2015, 6, 17121-17134.	1.8	41
11	Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 3694-3708.	1.8	27
12	IL-27 Driven Upregulation of Surface HLA-E Expression on Monocytes Inhibits IFN- $\gamma$ Release by Autologous NK Cells. <i>Journal of Immunology Research</i> , 2014, 2014, 1-7.	2.2	17
13	IL-27 in Human Secondary Lymphoid Organs Attracts Myeloid Dendritic Cells and Impairs HLA Class II $\alpha$ Restricted Antigen Presentation. <i>Journal of Immunology</i> , 2014, 192, 2634-2642.	0.8	20
14	Interleukin-30 Expression in Prostate Cancer and Its Draining Lymph Nodes Correlates with Advanced Grade and Stage. <i>Clinical Cancer Research</i> , 2014, 20, 585-594.	7.0	46
15	The antitumor potential of Interleukin-27 in prostate cancer. <i>Oncotarget</i> , 2014, 5, 10332-10341.	1.8	49
16	The IL-12 $\beta$ 2 gene functions as a tumor suppressor in human B cell malignancies. <i>Journal of Clinical Investigation</i> , 2014, 124, 2807-2807.	8.2	0
17	Hypoxia-inducible factor (HIF)-1 $\alpha$ suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. <i>Leukemia</i> , 2013, 27, 1697-1706.	7.2	104
18	The IL-18 Antagonist IL-18 $\alpha$ Binding Protein Is Produced in the Human Ovarian Cancer Microenvironment. <i>Clinical Cancer Research</i> , 2013, 19, 4611-4620.	7.0	40

#	ARTICLE	IF	CITATIONS
19	Absence of IL-12R $\beta$ 2 in CD33+CD38+ pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2R $\beta$ 3C-deficient mice. <i>Leukemia</i> , 2012, 26, 225-235.	7.2	7
20	Interleukin-27 Inhibits the Growth of Pediatric Acute Myeloid Leukemia in NOD/SCID/IL2R $\beta$ 3C-deficient Mice. <i>Clinical Cancer Research</i> , 2012, 18, 1630-1640.	7.0	50
21	Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. <i>Leukemia</i> , 2012, 26, 1365-1374.	7.2	48
22	Targeting acute myeloid leukemia cells with cytokines. <i>Journal of Leukocyte Biology</i> , 2012, 92, 567-575.	3.3	12
23	Anti-leukemic properties of IL-12, IL-23 and IL-27: Differences and similarities in the control of pediatric B acute lymphoblastic leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 310-318.	4.4	16
24	Mda-9/Syntenin Is Expressed in Uveal Melanoma and Correlates with Metastatic Progression. <i>PLoS ONE</i> , 2012, 7, e29989.	2.5	64
25	Human TCR $\beta$ T cells represent a novel target for IL-27 activity. <i>European Journal of Immunology</i> , 2012, 42, 1547-1552.	2.9	18
26	Cytokines and microRNA in pediatric B-acute lymphoblastic leukemia. <i>Cytokine and Growth Factor Reviews</i> , 2011, 22, 149-156.	7.2	15
27	Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. <i>Leukemia</i> , 2011, 25, 1815-1824.	7.2	59
28	HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. <i>Leukemia</i> , 2011, 25, 527-537.	7.2	39
29	Cytokines as Anti-Angiogenic Agents in Haematological Malignancies. <i>Current Cancer Drug Targets</i> , 2011, 11, 997-1004.	1.6	3
30	Interleukin-27 and interleukin-23 modulate human plasmacell functions. <i>Journal of Leukocyte Biology</i> , 2011, 89, 729-734.	3.3	40
31	Regulation of angiostatic chemokines driven by IL-12 and IL-27 in human tumors. <i>Journal of Leukocyte Biology</i> , 2011, 90, 875-882.	3.3	27
32	Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells. <i>Clinical Cancer Research</i> , 2011, 17, 6963-6970.	7.0	17
33	Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. <i>Blood</i> , 2010, 116, 3887-3898.	1.4	46
34	The enigmatic role of IL-12 in the pathogenesis of Sjögren's syndrome: Comment on article by Vosters J.L. et al. <i>Arthritis and Rheumatism</i> , 2010, 62, n/a-n/a.	6.7	1
35	Direct inhibition of human acute myeloid leukemia cell growth by IL-12. <i>Immunology Letters</i> , 2010, 133, 99-105.	2.5	34
36	Interleukin-27 Acts as Multifunctional Antitumor Agent in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2010, 16, 4188-4197.	7.0	88

#	ARTICLE	IF	CITATIONS
37	IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions. PLoS ONE, 2009, 4, e6119.	2.5	43
38	Interleukin-12 Receptor $\beta 2$ : From Cytokine Receptor to Gatekeeper Gene in Human B-Cell Malignancies. Journal of Clinical Oncology, 2009, 27, 4809-4816.	1.6	27
39	Chemokines in neuroectodermal tumour progression and metastasis. Seminars in Cancer Biology, 2009, 19, 97-102.	9.6	26
40	New Perspectives for Melanoma Immunotherapy: Role of IL-12. Current Molecular Medicine, 2009, 9, 459-469.	1.3	20
41	CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunology, Immunotherapy, 2008, 57, 541-548.	4.2	50
42	Constitutive expression of IL-12 $\beta 2$ on human multiple myeloma cells delineates a novel therapeutic target. Blood, 2008, 112, 750-759.	1.4	38
43	Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3996-4001.	7.1	83
44	CXCL12 Does Not Attract CXCR4+ Human Metastatic Neuroblastoma Cells: Clinical Implications. Clinical Cancer Research, 2006, 12, 77-82.	7.0	47
45	Methylation of the IL-12 $\beta 2$ Gene as Novel Tumor Escape Mechanism for Pediatric B-Acute Lymphoblastic Leukemia Cells. Cancer Research, 2006, 66, 3978-3980.	0.9	26
46	Lack of IL12 $\beta 2$ signaling predisposes to spontaneous autoimmunity and malignancy. Blood, 2005, 106, 3846-3853.	1.4	110
47	Mechanisms of immune evasion of human neuroblastoma. Cancer Letters, 2005, 228, 155-161.	7.2	76
48	Heterogeneous Expression of Interleukin-18 and Its Receptor in B-Cell Lymphoproliferative Disorders Deriving from Naïve, Germinal Center, and Memory B Lymphocytes. Clinical Cancer Research, 2004, 10, 144-154.	7.0	32
49	Immunogenicity of Human Neuroblastoma. Annals of the New York Academy of Sciences, 2004, 1028, 69-80.	3.8	48
50	Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma. Neoplasia, 2004, 6, 558-568.	5.3	216
51	Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. British Journal of Cancer, 2003, 88, 1527-1536.	6.4	31
52	Stromal Cell-Derived Factor-1 as a Chemoattractant for Follicular Center Lymphoma B Cells. Journal of the National Cancer Institute, 2000, 92, 628-635.	6.3	92
53	Expression and Function of IL-12 and IL-18 Receptors on Human Tonsillar B Cells. Journal of Immunology, 2000, 165, 6880-6888.	0.8	103
54	Ultrastructural and Functional Studies of the Interaction between IL-12 and IL-2 for the Generation of Lymphokine-Activated Killer Cells. Experimental Cell Research, 1999, 253, 440-453.	2.6	10

#	ARTICLE	IF	CITATIONS
55	Engrafted maternal T cells in human severe combined immunodeficiency: Evidence for a T H2 phenotype and a potential role of apoptosis on the restriction of T-cell receptor variable $\beta^2$ repertoire. Journal of Allergy and Clinical Immunology, 1998, 101, 131-134.	2.9	10
56	Tumor Necrosis Factor (TNF) Enhances the Locomotion of Low-Density Human Tonsillar B Lymphocytes through the Selective Triggering of Type II Receptor. Annals of the New York Academy of Sciences, 1997, 815, 364-366.	3.8	0
57	Transcriptional Repression by the Human Homeobox Protein EVX1 in Transfected Mammalian Cells. Journal of Biological Chemistry, 1995, 270, 27695-27701.	3.4	23
58	Differential DNA binding properties of three human homeodomain proteins. Nucleic Acids Research, 1992, 20, 4465-4472.	14.5	47